CO6290664A2 - Piperazinas sustituidas como antagonistas del receptor cb1 - Google Patents

Piperazinas sustituidas como antagonistas del receptor cb1

Info

Publication number
CO6290664A2
CO6290664A2 CO10007654A CO10007654A CO6290664A2 CO 6290664 A2 CO6290664 A2 CO 6290664A2 CO 10007654 A CO10007654 A CO 10007654A CO 10007654 A CO10007654 A CO 10007654A CO 6290664 A2 CO6290664 A2 CO 6290664A2
Authority
CO
Colombia
Prior art keywords
aryl
heteroaryl
alkyl
group
benzo
Prior art date
Application number
CO10007654A
Other languages
English (en)
Inventor
Eric Gilbert
Michael W Miller
Jack D Scott
Duane E Demong
Andrew Stamford
William J Greenlee
Chander Celly
Original Assignee
Intervet Internacional B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Internacional B V filed Critical Intervet Internacional B V
Publication of CO6290664A2 publication Critical patent/CO6290664A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

1.- Un compuesto de la Fórmula (I):o una sal, solvato. éster, o isómero del mismo farmacéuticamente aceptable, en donde: Ar1 y Ar2 son independientemente arilo o heteroarilo,en donde Ar1 es sustituido con uno o más grupos independientemente seleccionados a partir de Y1 o Y3, yAr2 es sustituido con uno o más grupos independientemente seleccionados a partir de Y1 o Y3; con la condición que cuando Ar2 es piridina o pirimidina, un nitrógeno de dicha piridina o pirimidina no esté en la posición para con relación al punto de unión al anillo de piperazina; siempre y cuando al menos uno de Ar1 o Ar2 es sustituido con al menos un grupo independientemente seleccionados a partir de Y3;n y m son independientemente 0 o 1;A es seleccionado a partir del grupo que consta de -C(O)-, -S(O)2-, -C(=N-OR2)-, y -(C(R2)2)q- en donde q es 1, 2, o 3;B es seleccionado a partir del grupo que consta de - N(R2)-, -C(O)-, y -(C(R3)2) r en donde r es 1, 2 o 3,con la condición que cuando B es - C(O)-, entonces A sea -C(O)- o - (C(R2)2)q-; X es seccionado a partir del grupo que consta de H, alquilo, -S-alquilo, -S(O)2 -alquilo, -S(O)2- cicloalquilo, - S(O)2-arilo, -S(O)2-heteroarilo, cicloalquilo, cicloalquilo benzo-fusionado-, heterocicloalquilo benzo- fusionado, heterocicloalquenilo benzo-fusionado, heterocicloalquilo, -C(R2) =C(R2) - arilo, -C(R2) =C(R2)- heteroarilo, - OR2, - O- alquileno-O- alquilo, - S- arilo, -N(R4)2, -NR4R6, -N(R6)2) - (C(R2) 2)s - heteroarilo, -C(O)- O-alquilo, -O-arilo, -O-heteroarilo, -C(O)arilo, -C(O)- heteroarilo, -N=O, -C(S-alquil) =N- S(O)2- arilo, -C(N(R2)2)=N- S(O) 2 -arilo, y - (C(R2) 2) s -arilo, en donde s es 0, 1, o 2, ...
CO10007654A 2007-06-28 2010-01-26 Piperazinas sustituidas como antagonistas del receptor cb1 CO6290664A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94687307P 2007-06-28 2007-06-28

Publications (1)

Publication Number Publication Date
CO6290664A2 true CO6290664A2 (es) 2011-06-20

Family

ID=39830038

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10007654A CO6290664A2 (es) 2007-06-28 2010-01-26 Piperazinas sustituidas como antagonistas del receptor cb1

Country Status (14)

Country Link
US (1) US8623873B2 (es)
EP (2) EP2548874A3 (es)
JP (1) JP2010531361A (es)
KR (1) KR20100051625A (es)
CN (1) CN101796033A (es)
AU (1) AU2008271178A1 (es)
BR (1) BRPI0814806A2 (es)
CA (1) CA2692268A1 (es)
CO (1) CO6290664A2 (es)
MX (1) MX2010000334A (es)
NZ (1) NZ582249A (es)
RU (1) RU2010102478A (es)
WO (1) WO2009005646A2 (es)
ZA (1) ZA201000395B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435790T3 (es) * 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
MX2008009354A (es) * 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
CA2660699A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
NZ582249A (en) 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists
PA8802101A1 (es) * 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
US8063088B2 (en) * 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
ES2523343T3 (es) * 2008-09-24 2014-11-25 Zach System Procedimiento de preparación de nebivolol
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
AU2011346746A1 (en) * 2010-12-23 2013-07-11 Intervet International B.V. Polymorphs of 3-chloro-4[(2R)-2
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN103304561B (zh) * 2013-06-21 2016-06-01 天津药物研究院 一类具有抗血栓作用的化合物
WO2023089612A1 (en) * 2021-11-19 2023-05-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peripheral cb1 receptor antagonists for treatment of lower urinary tract symptoms (luts)

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (es) 1966-03-12
GB1181322A (en) 1967-06-29 1970-02-11 Chugai Pharmaceutical Co Ltd Piperazine Derivatives and processes for preparing the same
US4229207A (en) 1975-08-15 1980-10-21 Ciba-Geigy Corporation Esters of 1,2-diphenyl-cyclohex-1-ene-4-carboxylic acid
IT1191845B (it) 1986-01-20 1988-03-23 Dompe Farmaceutici Spa Alchiloli derivati farmacologicamente attivi
CA1308352C (en) 1986-08-15 1992-10-06 James V. Peck Compositions comprising 1-oxohydrocarbyl-substituted azacyclohexanes
US4917896A (en) 1986-08-15 1990-04-17 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5073544A (en) 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
FI875101A (fi) 1986-12-03 1988-06-04 Tanabe Seiyaku Co Laktamderivat och preparat innehaollande dessa.
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
JPH03200758A (ja) 1989-12-28 1991-09-02 Konica Corp スルホン酸エステル誘導体及び含窒素６員環化合物の製造方法
US5332817A (en) 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5580883A (en) 1990-03-26 1996-12-03 Takeda Chemical Industries, Ltd. Aminobenzene compounds to prevent nerve cell degradation
CA2054816C (en) 1990-11-09 2002-06-18 Angel Sy Aromatic alkylation process
JPH04364175A (ja) 1991-02-08 1992-12-16 Konica Corp 含窒素６員環化合物の製造方法
US5185349A (en) 1991-03-08 1993-02-09 Warner-Lambert Company Substituted amide ACAT inhibitors lactone derivatives
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
CZ14294A3 (en) 1991-07-23 1994-07-13 Schering Corp Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof
US5234895A (en) 1992-06-19 1993-08-10 Imperial Chemical Industries Plc Arylpyridone herbicides
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
DE4305659A1 (de) 1993-02-24 1994-08-25 Heumann Pharma Gmbh & Co Verfahren zur Herstellung von 1,2,3,4,10,14b-Hexahydro-2-methyl-dibenzo[c,f]pyrazino[1,2-a]azepin und seiner Salze
US5508424A (en) 1993-03-26 1996-04-16 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
JP3200758B2 (ja) 1995-01-20 2001-08-20 モレックス インコーポレーテッド イジェクタ機構付きコネクタ
JPH09124643A (ja) 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
DE69621831T2 (de) 1995-12-18 2003-01-02 Fujisawa Pharmaceutical Co Piperazinderivative als tachykinin antagonisten
US5780480A (en) 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US20020128476A1 (en) 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
BR9808502A (pt) 1997-05-08 2000-05-23 Smithkline Beecham Corp Inibidores de protease
DK0981343T3 (da) 1997-05-14 2006-01-30 Atherogenics Inc Probucolmonoestere til behandling af kardiovaskulær og inflammatorisk sygdom
EP1007563A4 (en) 1997-06-12 2003-04-16 Smithkline Beecham Corp HM74A RECEPTOR
ES2257824T3 (es) 1998-01-28 2006-08-01 Warner-Lambert Company Llc Metodo para tratar la enfermedad de alzheimer.
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
WO2000035876A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
DK1140184T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
EP1196395A1 (en) 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated Cyclized amino acid derivatives
FR2799124B1 (fr) 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2804604B1 (fr) 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
DE10042447A1 (de) 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
KR100833089B1 (ko) 2000-12-21 2008-05-29 사노피-아벤티스 도이칠란트 게엠베하 신규한 1,2-디페닐아제티딘온 및 당해 화합물을 함유하는 지질 대사 장애를 치료하기 위한 약제학적 조성물
HUP0401073A2 (hu) 2000-12-21 2004-09-28 Aventis Pharma Deutschland Gmbh. Difenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
CA2432809C (en) 2000-12-21 2010-11-30 Schering Corporation Heteroaryl urea neuropeptide y y5 receptor antagonists
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
CN1275949C (zh) 2001-03-28 2006-09-20 先灵公司 2－吖丁啶酮中间体化合物的对映体选择性合成
EP1377834A2 (en) 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
HUP0402113A3 (en) 2001-09-21 2012-05-29 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
JP4266830B2 (ja) 2002-01-10 2009-05-20 日本電気株式会社 微小球体の液体による整列方法、および微小球体整列装置
US20030171588A1 (en) 2002-03-07 2003-09-11 Kahl Jeffrey D. 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
US20030109673A1 (en) 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor
US20030139343A1 (en) 2002-12-04 2003-07-24 Shyam Ramakrishnan Regulation of human hm74-like g protein coupled receptor
MXPA05007114A (es) 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
MXPA05007115A (es) 2003-01-02 2005-11-16 Hoffmann La Roche Nuevos agonistas inversos del receptor cb 1.
US20040167185A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-3 receptor
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
AU2005214378A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2005082352A1 (en) 2004-02-20 2005-09-09 Aventis Pharmaceuticals Inc. Oxydecahydronaphthalene modulators of hm74
MXPA06008612A (es) 2004-02-20 2007-01-25 Aventis Pharma Inc Derivados de furosemida como modulares de hm74 y su uso para el tratamiento de la inflamacion.
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
JP4364175B2 (ja) 2005-08-01 2009-11-11 株式会社東芝 乗算器及びこれを用いる無線通信装置
GB0523609D0 (en) * 2005-11-19 2005-12-28 Vernalis R&D Ltd Piperazine derivatives
AR058985A1 (es) 2006-01-13 2008-03-05 Schering Corp Diaril piperidinas como moduladores de cb1.
MX2008009354A (es) 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
WO2008130616A2 (en) 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
JP2010531360A (ja) 2007-06-28 2010-09-24 インターベット インターナショナル ベー． フェー． Ｃｂ１拮抗剤としてのピペラジンの使用
NZ582249A (en) 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists
US20100286160A1 (en) 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists

Also Published As

Publication number Publication date
RU2010102478A (ru) 2011-08-10
MX2010000334A (es) 2010-04-22
US20090105208A1 (en) 2009-04-23
EP2170846A2 (en) 2010-04-07
US8623873B2 (en) 2014-01-07
KR20100051625A (ko) 2010-05-17
WO2009005646A3 (en) 2009-03-19
JP2010531361A (ja) 2010-09-24
AU2008271178A2 (en) 2010-03-04
CN101796033A (zh) 2010-08-04
BRPI0814806A2 (pt) 2015-02-03
AU2008271178A1 (en) 2009-01-08
CA2692268A1 (en) 2009-01-08
WO2009005646A2 (en) 2009-01-08
ZA201000395B (en) 2010-11-24
NZ582249A (en) 2012-06-29
EP2548874A3 (en) 2013-05-15
EP2548874A2 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
CO6290664A2 (es) Piperazinas sustituidas como antagonistas del receptor cb1
AR054998A1 (es) Piperazinas sustituidas como antagonistas de cb1, composicion farmaceutica y uso del compuesto para la manufactura de medicamentos
ME00004B (me) Derivati pirimidina
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
AR091079A1 (es) Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
CR9048A (es) Analogos de anilino-pirimidina
MY161903A (en) Substituted piperidines as ccr3 antagonists
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
NZ627036A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PE20131380A1 (es) Agente de control de plagas
AR068967A1 (es) Compuestos de ciclohexandiona, proceso para la preparacion de los mismos, compuestos intermediarios, metodo de control de hierbas y malezas, y composicion herbicida
AR059021A1 (es) Moduladores de receptores cannabinoides
CO6150145A2 (es) Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR074165A1 (es) Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas
AR057894A1 (es) Derivados de tiofeno
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
AR078270A1 (es) Inhibidores de jak (quinasas janus)
AR104262A1 (es) Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas
AR056418A1 (es) Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento
AR061455A1 (es) Acidos fosfinicos y sus derivados de azufre y metodos para su preparacion
PE20071324A1 (es) Metodos de usar derivados de 3-piridilo como pesticidas
AR069387A1 (es) Compuestos de cicloalquiloxi -y heterocicloalquiloxipiridina como moduladores del receptor de histamina h3
CL2022000892A1 (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4

Legal Events

Date Code Title Description
FC Application refused